| abstract |
REFERS TO COMPOUNDS DERIVED FROM 2-MERCAPTOCYCLOPENTANOCARBOXYLIC ACID OF FORMULA (I) WHERE R1 IS H, COR4, AMONG OTHERS, WHERE R4 IS AN ALKYL (C1-C6) OR ARYL; R2 IS NR5R6, NITROGEN HETEROCYCLIC, ARYL OR HETEROARYL, WHERE R5 AND R6 ARE EACH H OR ALKYL (C1-C6); R3 IS H O ALKYL (C1-C6); m IS 1 TO 6; n IS FROM 0 TO 2. THE PREFERRED COMPOUNDS ARE: ACID (1R, 2S) -1- (3-AMINOPROPYL) -2-MERCAPTOCYCLOPENTANOCARBOXYL TRIFLUOROACETATE, ACID (1R, 2S) -2-ACETYLTIO-1- (3-AMINOPROPYL) - CYCLOPENTANOCARBOXYL HYDROCHLORIDE, ACID (1R, 2S) -1- (3-AMINOPROPYL) -2-MERCAPTOCYCLOPENTANOCARBOXYL HYDROCHLORIDE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF PLASMATIC PROCARBOXIPEPTIDASE B IN ITS ACTIVE FORM (TAFIa) AND ARE USEFUL IN THE TREATMENT OF MYOCARDIAL INFARCTION, ANGINA PEAK, CEREBRAL VASCULAR ACCIDENT, VENOUS THROMBOSIS |